Prediction of Neuropsychiatric Adverse Events Associated with Long-Term Efavirenz Therapy, Using Plasma Drug Level Monitoring
Open Access
- 1 December 2005
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (11) , 1648-1653
- https://doi.org/10.1086/497835
Abstract
Background. Data on long-term central nervous system (CNS) toxicity associated with efavirenz therapy are scarce, and risk factors remain largely unkKeywords
This publication has 15 references indexed in Scilit:
- Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamineNeurology, 2005
- Long-Term Neuropsychiatric Disorders on Efavirenz-Based ApproachesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Analyzing Sleep Abnormalities in HIV‐Infected Patients Treated with EfavirenzClinical Infectious Diseases, 2004
- Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infectionClinical Pharmacology & Therapeutics, 2003
- Population pharmacokinetics of nevirapine in an unselected cohort of HIV‐1‐infected individualsBritish Journal of Clinical Pharmacology, 2002
- Safety and Tolerance of Efavirenz in Different Antiretroviral Regimens: Results from a National Multicenter Prospective Study in 1,033 HIV-Infected PatientsHIV Research & Clinical Practice, 2002
- Higher Efavirenz Plasma Levels Correlate With Development of InsomniaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Preliminary Data of a Prospective Study on Neuropsychiatric Side Effects After Initiation of EfavirenzJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- EfavirenzDrugs, 1998